Journal
Blood Advances
Publication Date
5-26-2026
Volume
10
Issue
10
First Page
3676
Last Page
3689
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2025017519
Rights and Permissions
Gotlib J, Reiter A, Radia DH, Álvarez-Twose I, Deininger MW, George TI, Panse J, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lübke J, Bidollari I, Lin HM, Rylova S, Dimitrijević S, Muñoz-González JI, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. Blood Adv. 2026 May 26;10(10):3676-3689. doi: 10.1182/bloodadvances.2025017519. © 2026 American Society of Hematology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Gotlib, Jason; Oh, Stephen T; and et al., "Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study." Blood Advances. 10, 10. 3676 - 3689. (2026).
https://digitalcommons.wustl.edu/oa_4/7213
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
